Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 24, No 6 (February 20), 2006: pp. 884-890
© 2006 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.02.4505

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Khong, P.-L.
Right arrow Articles by Chan, G. C.F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khong, P.-L.
Right arrow Articles by Chan, G. C.F.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

White Matter Anisotropy in Post-Treatment Childhood Cancer Survivors: Preliminary Evidence of Association With Neurocognitive Function

Pek-Lan Khong, Lucullus H.T. Leung, Amy S.M. Fung, Daniel Y.T. Fong, Deqiang Qiu, Dora L.W. Kwong, Gaik-Cheng Ooi, Grainne McAlanon, Guang Cao, Godfrey C.F. Chan

From the Departments of Diagnostic Radiology, Clinical Oncology, Clinical Psychology, Nursing Studies, Psychiatry, Paediatric and Adolescent Medicine, Queen Mary Hospital, The University of Hong Kong; GE Medical Systems Asia, Hong Kong, China

Address reprint requests to Pek-Lan Khong, Department of Diagnostic Radiology, Blk K, Rm 406, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Rd, Hong Kong; e-mail: plkhong{at}hkucc.hku.hk


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 Authors' Disclosures of...
 Author Contributions
 REFERENCES
 
PURPOSE: We aim to determine if the loss of white matter fractional anisotropy (FA), measured by diffusion tensor magnetic resonance imaging (DTI), in post-treatment childhood medulloblastoma (MED) and acute lymphoblastic leukemia (ALL) survivors correlate with intelligence quotient (IQ) scores.

MATERIALS AND METHODS: MED and ALL survivors (n = 30; 20 male, 10 female; age range, 6.0 to 22.1 years; mean, 13.1 years) were recruited for DTI and IQ tests. In this cross-sectional study, age-matched normal control (n = 55; 32 male, 23 female; age range, 6.0 to 23 years; mean, 12.1 years) DTI was obtained to compute percentage difference in white matter FA ({Delta}FA%) for each patient compared with the age-matched control group. Multivariate regression analysis was performed to determine the relationships between {Delta}FA%, age at treatment, irradiation dose, time interval from treatment, and full-scale IQ (FSIQ), verbal IQ (VIQ), and performance IQ (PIQ). Receiver operating characteristics curves were used to determine the best {Delta}FA% cutoffs for predicting FSIQ, VIQ, and PIQ of less than 85.

RESULTS: {Delta}FA% had a significant effect on FSIQ (adjusted r2 = 0.439; P < .001), VIQ (adjusted r2 = 0.237; P = .028), and PIQ (adjusted r2 = 0.491; P < .001) after adjusting for the effects of age at treatment, irradiation dose, and time interval from treatment. The best {Delta}FA% value to predict less than 85 scores in FSIQ, VIQ, and PIQ was –3.3% with specificities of 100% and sensitivities ranging from 77.8% to 87.5%.

CONCLUSION: Our preliminary findings suggest that white matter FA may be a clinically useful biomarker for the assessment of treatment-related neurotoxicity in post-treatment childhood cancer survivors.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 Authors' Disclosures of...
 Author Contributions
 REFERENCES
 
Treatment-induced neurotoxicity is a major cause of neurobehavioral morbidity in childhood cancer survivors affecting diverse aspects of cognitive function, especially attention, memory, and processing speed, which, in turn, affect intelligence quotient (IQ) and academic achievement.1-7 With therapeutic advancements and improving long-term survivals, there is a greater and more urgent need for attention to neurocognitive outcomes, an important domain contributing to the quality of life of these children.

The assessment of treatment-induced neurotoxicity using conventional magnetic resonance neuroimaging techniques have been limited, with most studies reporting a lack of correlation between the presence of leukoencephalopathy on conventional magnetic resonance imaging (MRI) and clinical symptoms or neurocognitive tests.8-11 Advanced MRI techniques have shown more promising results. Volumetric measurements of normal appearing white matter in medulloblastoma (MED) survivors have been found to be reduced compared with normal controls,12 and the severity of volume loss correlates with young age at cranial irradiation,12 cranial irradiation dose, and IQ scores.5,6,12 This supports the fact that cerebral white matter is the neuroanatomic substrate for treatment-induced neurotoxicity. Also, magnetic resonance spectroscopy studies have generally shown a reduction in N-acetyl aspartate ratios in the white matter of childhood acute lymphoblastic leukemia (ALL) children, although no correlation has been found with neurocognitive scores.13,14

We have used a new sequence in MRI, diffusion tensor MRI (DTI), to measure the loss of fractional anisotropy (FA) in the white matter of childhood cancer survivors.15,16 DTI is a technique that is able to quantitate the diffusion of water molecules in the brain. In white matter, the diffusion process is highly directional because of axonal fibers running in parallel, making this technique advantageous for the assessment of white matter.17 This property, termed diffusion anisotropy, can be quantified by the index FA. When white matter microstructure is disrupted because of pathology, the abnormality can be detected and quantified by the loss of FA. Compared with volumetric measurements, this method potentially has the advantage of more sensitive detection of subtle and early changes that occur in the microstructure and organization of white matter fiber tracts. We have shown that white matter FA (WMFA) is less in childhood MED survivors compared with normal control patients,15,16 and that the difference correlates with known risk factors of neurotoxicity,18 suggesting that FA may be used as a biomarker of treatment-induced white matter damage reflecting the status of tissue microstructure and architecture. In a cross-sectional study of childhood MED and ALL survivors, we aim to determine if FA measurement correlates with neurocognitive function, by the assessment of IQ scores.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 Authors' Disclosures of...
 Author Contributions
 REFERENCES
 
Patient Demographics
Consecutive MED and ALL survivors who were free of the primary disease, completed treatment at least 1 year ago, and were at least 6 years of age were recruited from the Pediatric Oncology Unit of our hospital for DTI and IQ tests. Informed consent was obtained from the patient or parent and the study was approved by the hospital institutional review board. A total of 30 patients (20 male, 10 female; age range, 6.0 to 22.1 years; mean age, 13.1 years) were recruited, of which 12 were MED survivors and 18 were ALL survivors. All the MED survivors belonged to our previous cohort studied for the association of FA with risk factors of neurotoxicity.18 IQ scores were not analyzed then.

All MED survivors (9 male, 3 female; age range, 6 to 20.6 years; mean, 11.8 years) underwent tumor resection, craniospinal irradiation, and chemotherapy. The whole brain was irradiated with lateral opposing fields 23.4 to 40 Gy in 1.8 to 2 Gy daily fractions. Afterward, additional boost was given to the posterior cranial fossa with reduced lateral opposing fields or with three-dimensional conformal radiotherapy. Three patients had posterior cranial fossa boost with three-dimensional conformal radiotherapy. Total dose to the posterior cranial fossa ranged from 50 to 55.8 Gy. Total craniospinal irradiation dose was 23.4 Gy (n = 3), 30.6 Gy (n = 3), 36 Gy (n = 5), and 40 Gy (n = 1). The variation in dosage is, in part, because of the change of the protocol in recent years and also, in part, because of the differences in their disease status. Chemotherapy regime was vincristine, cyclophosphamide, cisplatin and VP16 (baby Pediatric Oncology Group protocol) for children diagnosed before 2000 or CCNU (lomustine), cisplatin, and vincristine (CCV protocol) for children diagnosed after 2000.

All ALL survivors (11 male, 7 female; age range, 6.8 to 22 years; mean, 13.9 years) were treated with standardized intrathecal and systemic chemotherapy regimes. Patients received intrathecal methotrexate and high-dose methotrexate in doses varying from 2 to 5 g/m2 for three to four doses. Before October 1997, chemotherapy was according to the HKALL93 protocol (based on the United Kingdom Medical Research Council protocols for childhood ALL, UKALLX1). From October 1997, the chemotherapy regime was altered to the HKALL97 protocol (based on the Berlin-Frankfurt-Munster study group protocol, ALL-BFM 95). The cranial irradiation dose for high-risk patients was 18 Gy in the HKALL93 protocol and 12 Gy in the HKALL97 protocol. Nine ALL survivors underwent irradiation for CNS prophylaxis and/or CNS disease (6 males, 3 females; age range, 7.4 to 22 years; mean, 14.8 years) and nine did not (5 males, 4 females; age range, 6.8 to 17.7 years; mean, 13.1 years). Cranial irradiation dose was 12 Gy (n = 2), 18 Gy (n = 5), and 24 Gy (n = 2, for CNS involvement).

Patient demographic data is summarized in Table 1. Fifty-five healthy age-matched children (32 male, 23 female; age range, 6.0 to 23 years; mean, 12.1 years) were selected as controls for DTI scans after institutional review board approval and informed consent was obtained from the subjects, patients, or parents. These subjects were volunteer healthy control subjects or patients who underwent MRI of the brain for clinical indications such as headache or congenital sensorineural hearing loss and were subsequently confirmed to have no neurologic deficit by clinical examination and normal MRI scans. The control subjects were imaged with the same DTI protocol as the patients and were divided into four groups by age: Group A (n = 13; age range, 6.0 to 8.9 years; mean, 7.7 years), Group B (n = 18; age range, 9.0 to 11.9 years; mean, 10.2 years), Group C (n = 11; age range, 12.0 to 14.9 years; mean, 13.6 years), and Group D (n = 13; age range, 15.0 to 23.0 years; mean, 17.9 years) for analysis (see below for {Delta}FA% calculation).


View this table:
[in this window]
[in a new window]
 
Table 1. Showing Patient Demographics, WMFA, {Delta}FA%, and Treatment Protocols of 30 ALL and MED Patients

 
Data Acquisition
MRI was performed using a Signa 1.5 Tesla imager (General Electric Medical Systems, Milwaukee, WI) with a standard head coil. DTI data was acquired using single-shot spin-echo echo-planar imaging with TR = 10,000 ms, TE = 100 ms, acquisition matrix = 128 x 128 and field of view = 28 cm. Using a slice thickness of 5 mm with 1.5 mm gap, images were acquired through the entire brain (18 or 19 images). Diffusion-sensitizing gradient encoding was applied in 25 directions by using a diffusion-weighted factor b = 1,200 s/mm2, and one image was acquired without use of a diffusion gradient, ie, b = 0 s/mm2. The DTI imaging time was approximately 5 minutes.

Image Processing
The DTI data were processed using FUNCTOOL (GE Medical Systems, USA) to obtain the FA map. All image manipulations were done using SPM2 (Wellcome Department of Imaging Neuroscience, Institute of Neurology, UK) and MATLAB 6.5 (The MathWorks Inc, Natick, MA). Computation of the quantitative index, mean WMFA from the FA map was performed for each patient and control subject as described previously.18 The mean WMFA of the control subjects were grouped into the respective four age groups (Group A-D) and the mean WMFA of each age group was obtained.

{Delta} Fractional Anisotropy ({Delta}FA%) Calculation
As it is known that WMFA increases nonlinearly with age, the corresponding age-matched control group mean WMFA was used as a reference value to calculate the percentage difference in WMFA ({Delta}FA%) of each patient. The same reference WMFA value was used in the calculation of {Delta}FA% for multiple patients, depending on patient age. These reference values were required for comparison in our cohort as these values are scanner and sequence specific and cannot be quoted from the literature. {Delta}FA% for each patient was computed by (WMFA of patient –WMFA of the age-matched control group)/WMFA of age-matched control group x 100%. As this is not a longitudinal study, note that {Delta}FA% used in this study does not represent change within an individual but rather reflects a difference in FA of each individual compared with the corresponding age-matched control group.

Neuropsychologic Tests
IQ scores were obtained for all patients within 0 to 476 days of the DTI scans, with 22 patients (73.3%) having had IQ tests performed within 4 months of DTI scans. All but two IQ tests were performed within 1 year of the DTI scans. We used the Hong Kong Wechsler Intelligence Scales for Children (HK-WISC) for subjects younger than 16 years of age and the Wechsler Adult Intelligence Scale-Revised (WAIS-R) for those 16 years of age and older. The HK-WISC is an adaptation of the WISC taking into consideration the cultural background and range of experience of local Hong Kong children. Verbal IQ (VIQ), performance IQ (PIQ), and full-scale IQ (FSIQ) were assessed.

Statistical Analysis
We used the Mann-Whitney U test to compare age, educational level, and socioeconomic status (according to the definition by the United Kingdom office of population consensus and surveys 1991) and Fisher's exact test to compare sex differences between the control and patient groups. Analysis of variance (ANOVA) was performed to compare neurocognitive measures, {Delta}FA%, and patient demographic factors between the three treatment groups, ALL without irradiation, ALL with irradiation, and MED survivors. We performed posthoc tests among the three treatment groups using Bonferroni corrections. To test for trend of {Delta}FA% over the three treatment groups, we used linear contrast. Normality assumption of the ANOVA analysis was checked and was met. Multiple linear regression analysis was used to study the effects of irradiation dose and age at treatment on {Delta}FA% after the cubic root transformation. The transformation was made because of inadequate normality before transformation. To determine the relationships between independent variables—sex, education level, socioeconomic status, and known neurotoxicity risk factors—age at treatment, irradiation dose and time interval from treatment, and {Delta}FA% and dependent variables—FSIQ, VIQ, and PIQ—a two-stage multivariate regression analysis was performed to account the correlation among the dependent variables. The independent variables were clustered into two groups. Group 1 included sex, education level, and socioeconomic status. Group 2 included known neurotoxicity risk factors, age at treatment, irradiation dose and time interval from treatment, and {Delta}FA%. The two groups were defined such that variables in group 1 are general factors that may affect IQ and group 2 are variables that have been shown to affect IQ and {Delta}FA% (ie, risk factors of neurotoxicity) in this type of patient group. In stage 1, a multivariate analysis was performed to examine the effect of each variable in group 1. In stage 2, a multivariate analysis was performed on all variables in group 2 as well as those variables significant in stage 1.

We also tested the unadjusted effects of {Delta}FA% on the IQ scores using {Delta}FA% as the only independent variable. All regression models were checked for adequacy by using the standardized residuals. Normal assumptions were met. Receiver operating characteristics curves were used to determine the best {Delta}FA% cutoffs for predicting a FSIQ, VIQ, and PIQ of less than 85. Specifically, the best cutoff value was taken as the one that maximized the Youden index, ie, sensitivity + specificity –1. We computed the sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, and negative likelihood ratio of the best {Delta}FA% cutoffs.

All statistical analyses were performed using the statistical package SPSS for Windows (Version 11.0, SPSS, Chicago, IL). A P value of less than .05 was considered to indicate statistical significance.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 Authors' Disclosures of...
 Author Contributions
 REFERENCES
 
Control and Patient Group Demographics
There were no significant differences found between age (Mann-Whitney U test, P = .316), sex (Fisher's exact test, P = .492), educational levels (Mann-Whitney U test, P = .899), and socioeconomic status (Mann-Whitney U test, P = .306) between the control and patient groups.

Mean WMFA and {Delta}FA%
The mean WMFA of Groups A, B, C, and D control patients were 0.348 (standard deviation [SD], 0.016), 0.355 (SD, 0.010), 0.359 (SD, 0.012), and 0.358 (SD, 0.007), respectively. The mean WMFA and mean {Delta}FA% of all 30 patients was 0.346 (SD, 0.019) and –2.30% (SD, 4.94%), respectively. Mean WMFA and mean {Delta}FA% of the three treatment groups are summarized in Table 1. There were no significant differences in age at treatment between the three treatment groups but MED survivors had a significantly shorter time interval from treatment compared with the ALL survivors (ANOVA, P = .014). We found a level of significance that suggested a trend toward significant differences in {Delta}FA% between the three treatment groups with MED survivors having the largest {Delta}FA%, ALL survivors with irradiation having slightly smaller {Delta}FA%, and ALL survivors without irradiation having the least {Delta}FA% (ANOVA, P = .066). Multiple linear regression analyses found that irradiation dose (effect, –0.040; SE, 0.016; P = .018) and age at treatment (effect, 0.106; SE, 0.048; P = .035) had a significant effect on the cubic root of {Delta}FA%.

IQ Scores
Mean FSIQ, VIQ, and PIQ of all 30 patients was 106.03 (SD, 17.05), 110.57 (SD, 15.77), and 99.57 (SD, 17.25), respectively. IQ scores and subtest scores of the three treatment groups are summarized in Table 2. By ANOVA analysis, there were no significant differences in IQ scores between the three treatment groups, although MED survivors had the lowest scores in FSIQ, VIQ and the verbal subtests, information, and arithmetic, followed by ALL survivors with irradiation and ALL survivors without irradiation (Table 2). FSIQ scores were below average (< 85) in five patients (five of 30, 16.67%), of which three were MED survivors (three of 12, 25%) and two were ALL survivors (two of 18, 11.11%, one with and one without irradiation). VIQ scores were below average (< 85) in three patients (three of 30, 10%), of which two were MED survivors and one was an ALL survivor (without irradiation). PIQ scores were below average (< 85) in six patients (six of 30, 20%), of which four were MED survivors (four of 12, 30%) and two were ALL survivors (two of 18, 11.11%, one with and one without irradiation). Evaluation of the IQ subtests revealed that at least one below average subtest score (< 7) was found in 10 ALL survivors (10 of 18, 55.6%) and six MED survivors (six of 12, 50%). The percentage frequencies of below average scores for each subtest were as follows: information, 16.7%; similarities, 3.3%; arithmetic, 6.7%; vocabulary, 14.3% and comprehension, 3.3%; picture completion, 3.3%; picture arrangement, 10%; block design, 10%; object assembly, 16.7%; and coding/digit symbol, 34.5%.


View this table:
[in this window]
[in a new window]
 
Table 2. Showing the IQ Scores of 30 ALL and MED Survivors

 
Statistical Analysis for {Delta}FA% Versus IQ Scores
Multivariate regression analysis with {Delta}FA% as the only independent variable found significant correlations with FSIQ (Fig 1; adjusted r2 = 0.434; P < .001), VIQ (Fig 2; adjusted r2 = 0.234; P = .004), and PIQ (Fig 3; adjusted r2 = 0.515; P < .001). Note that the overall significance of {Delta}FA% with the three IQ scores was significant (Wilk's Lambda test, P < .001). In stage 1 of multivariate regression analysis using sex, educational level, and socioeconomic status as independent variables, we found that these variables were all not significant factors affecting IQ scores (Wilk's lambda test, P = .686, P = .490, and P = .232, respectively). Therefore, these variables were excluded from further multivariate analysis. In stage 2, after adjusting for the effects of age at treatment, irradiation dose and time interval from treatment, {Delta}FA% remained as a significant factor of FSIQ (adjusted r2 = 0.439; P < .001), VIQ (adjusted r2 = 0.237; P = .028), and PIQ (adjusted r2 = 0.491; P < .001; Table 3).


Figure 1
View larger version (8K):
[in this window]
[in a new window]
 
Fig 1. Scatter plot of FSIQ (full-scale intelligence quotient) and {Delta}FA% (percentage difference in white matter fractional anisotropy).

 

Figure 2
View larger version (8K):
[in this window]
[in a new window]
 
Fig 2. Scatter plot of PIQ (performance intelligence quotient) and {Delta}FA% (percentage difference in white matter fractional anisotropy).

 

Figure 3
View larger version (8K):
[in this window]
[in a new window]
 
Fig 3. Scatter plot of VIQ (verbal intelligence quotient) and {Delta}FA% (percentage difference in white matter fractional anisotropy).

 

View this table:
[in this window]
[in a new window]
 
Table 3. Showing Multivariate Regression Analysis of the Relationships Between Independent Variables; {Delta}FA% and Neurotoxicity Risk Factors; Age at Treatment, Irradiation Dose and Time Interval From Treatment and Dependent Variables; Full-Scale IQ, Verbal IQ, and Performance IQ

 
Using 85 as a cutoff for below average IQ score, receiver operating characteristic curve analysis showed that the best {Delta}FA% value to predict less than 85 scores in FSIQ, VIQ, and PIQ was –3.3%. The sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, and negative likelihood ratio for predicting FSIQ less than 85, VIQ less than 85, and PIQ less than 85 using {Delta}FA % = –3.3% are presented in Table 4.


View this table:
[in this window]
[in a new window]
 
Table 4. Showing Sensitivity, Specificity, PPV, NPV, LR+, and LR– of Full-Scale IQ < 85, Verbal IQ < 85, and Performance IQ < 85 When {Delta}FA% = –3.3%

 

    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 Authors' Disclosures of...
 Author Contributions
 REFERENCES
 
In a cohort of childhood post-treatment MED and ALL survivors, we found that {Delta}FA% (difference between patient FA and age-matched healthy control group FA normalized to the control group FA) of the white matter is significantly correlated with FSIQ, VIQ, and PIQ before and after adjusting for age at treatment, irradiation dose, and time interval since treatment. In addition, a {Delta}FA% cutoff of –3.3% provided a high specificity (100%), high negative predictive value (100%), and low negative likelihood ratio (0) for FSIQ and PIQ of less than 85. Together with high positive likelihood ratios, our results suggest that FA is a clinically useful indicator of cognitive outcome in this cohort of childhood cancer survivors. Positive predictive values were found to be moderate and this can, in part, be explained by the low prevalence of IQ scores less than 85 in our cohort.

It has been shown that white matter FA increases nonlinearly with age with the steepest increase occurring in the first few years of life, reaching asymptote at about 6 years in the internal capsule and corpus callosum and at about 8 years in the peripheral white matter of the centrum semiovale.19-22 This is attributed to several factors, including myelination, and increases in the number of axons, axonal diameter, and fiber coherence. Hence, we have used age-matched patient controls to derive the {Delta}FA% for each patient.

The association of DTI indices with cognitive function has been shown in both normal and diseased populations. Nagy et al23 found that the development of cognitive abilities in childhood is correlated with maturation of white matter; specifically, working memory and reading abilities were found to correlate with increased FA in the superior and inferior left frontal lobe and the left temporal lobe, respectively. Peng et al24 studied children with early chronic malignant phenylketonuria and found that VIQ, PIQ, and FSIQ were related to alteration of diffusion indices in the parieto-occipital white matter. Similar correlations have been found in minimal cognitive impairment and Alzheimer's disease,25 ischemic leukoaraiosis,26 and relapsing-remitting multiple sclerosis.27 In our cohort of childhood cancer survivors, apart from white matter damage from cranial irradiation and chemotherapy, contributory causes of cognitive decline in MED survivors include the primary effects of the tumor in the cerebellum, cerebellar resection,28,29 and its complications such as posterior fossa syndrome and hydrocephalus;30 and in ALL survivors, cortical atrophy and mineralizing microangiopathy are known sequelae of intrathecal methotrexate chemotherapy, which affect cognition.31 Therefore, white matter FA, which could be an indicator of myelin and/or axonal integrity, only partially accounts for cognitive function in our cohort.

We note that the IQ scores of our cohort are relatively high compared with other studies, especially the MED survivors. Mulhern et al12 and Palmar et al34 found the IQ scores in MED survivors to be between 80 and 85. The IQ scores of ALL survivors have been found to be generally higher and often within the normal range.31 This is presumably partly because of the lower cranial irradiation dose in these patients. However, most studies have found some decline in one or more aspects of cognitive function when individual subsets scores are assessed.31 Since the cognitive impairment in ALL survivors is relatively mild and difficult to detect, this may be evident only when a matching control group IQ is used for comparison.32,33 High IQ scores in our cohort may reflect selection bias, a relatively high age at diagnosis and treatment of our MED group (mean age at diagnosis, 8.5 years, which is older than in most studies), and conservative irradiation doses. In our cohort, the lack of a significant difference in the IQ scores between MED survivors and ALL survivors may be because IQ tests were performed at a shorter interval since treatment in the former group, as it has been shown that IQ scores progressively decline with interval since treatment.4,34,35 The subtest with most frequent below average score in our cohort was digit symbol/coding (34.5%). This subtest is a test of psychomotor performance and involves motor persistence, sustained attention, response speed, and visuomotor coordination. It is considered a sensitive test of brain damage and tends to be affected regardless of the locus of the lesion and is in keeping with the diffuse white matter damage found after whole brain irradiation.

Our study is limited by a relatively small, heterogeneous cohort with varied treatment protocols and disease processes. Our findings may, therefore, only be specific to this cohort of patients and should not be generalized to other types of cohorts. In addition, the small subject numbers may result in the lack of power for determination of the effect of some factors in the multivariate regression analysis. The age ranges applied to the control subjects in this study are arbitrary and were selected such that they were reasonably small. The use of mean FA reference values of an age-range, albeit small, instead of exact age-match is another limitation that has been discussed in our previous publication.18 The cross-sectional nature of the study does not allow the assessment of developmental trends in IQ and FA. In a prospective study, if FA decline is found to herald IQ deterioration and is able to indicate damage before the completion of treatment, it may be used as a parameter to effect change in treatment strategy. Also, two patients had a prolonged time lag of more than 1 year between IQ test and DTI, which may have affected the accuracy of our results. Finally, in the assessment of cognitive function, we did not evaluate more specific tests to tap specific cognitive abilities, which have been reported to decline after cranial irradiation, for example, memory and learning, attention and information processing speed. These tests may be more sensitive to the detection of cognitive decline and it may be possible that some of these tests have a stronger correlation with {Delta}FA%. Nevertheless, our preliminary observations warrant prospective, larger scale studies and further research in this area.

In conclusion, our findings suggest that DTI, using FA as a biomarker, may be a clinically useful tool for the assessment of treatment-related neurotoxicity and can be used as an adjunct to IQ scores. Longitudinal studies should be performed with close time points after treatment to determine the patterns of FA change and if loss of FA can be used to predict subsequent IQ decline. Apart from the assessment of neurotoxicity, this biomarker may potentially be useful in the assessment of timing and application of neurotoxic treatments and to test the effectiveness of neuroprotective drugs.


    Authors' Disclosures of Potential Conflicts of Interest
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 Authors' Disclosures of...
 Author Contributions
 REFERENCES
 
The authors indicated no potential conflicts of interest.


    Author Contributions
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 Authors' Disclosures of...
 Author Contributions
 REFERENCES
 

Conception and design: Pek-Lan Khong, Lucullus H.T. Leung, Daniel Y.T. Fong, Godfrey C.F. Chan

Financial support: Pek-Lan Khong, Gaik-Cheng Ooi, Guang Cao, Godfrey C.F. Chan

Administrative support: Pek-Lan Khong, Gaik-Cheng Ooi, Guang Cao

Provision of study materials or patients: Pek-Lan Khong, Lucullus H.T. Leung, Amy S.M. Fung, Dora L.W. Kwong, Grainne McAlanon, Godfrey C.F. Chan

Collection and assembly of data: Pek-Lan Khong, Lucullus H.T. Leung, Amy S.M. Fung, Deqiang Qiu, Dora L.W. Kwong, Grainne McAlanon, Godfrey C.F. Chan

Data analysis and interpretation: Pek-Lan Khong, Lucullus H.T. Leung, Amy S.M. Fung, Daniel Y.T. Fong, Deqiang Qiu, Dora L.W. Kwong, Grainne McAlanon, Godfrey C.F. Chan

Manuscript writing: Pek-Lan Khong, Lucullus H.T. Leung, Amy S.M. Fung, Daniel Y.T. Fong, Dora L.W. Kwong, Godfrey C.F. Chan

Final approval of manuscript: Pek-Lan Khong, Lucullus H.T. Leung, Amy S.M. Fung, Daniel Y.T. Fong, Deqiang Qiu, Dora L.W. Kwong, Gaik-Cheng Ooi, Grainne McAlanon, Guang Cao, Godfrey C.F. Chan

 


    NOTES
 
Supported by Hong Kong RGC CERG Grant Ref: HKU 7416/03M.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 Authors' Disclosures of...
 Author Contributions
 REFERENCES
 
1. Packer RJ, Sposto R, Atkins TE, et al: Quality of life in children with primitive neuroectodermal tumors (medulloblastoma) of the posterior fossa. Pediatr Neurosci 13:169-175, 1987[Medline]

2. Johnson DL, McCabe MA, Nicholson HS, et al: Quality of long-term survival in young children with medulloblastoma. J Neurosurg 80:1004-1010, 1994[Medline]

3. Walter AW, Mulhern RK, Gaijar A, et al: Survival and neurodevelopmental outcome of young children with medulloblastoma at St. Jude Children's Research Hospital. J Clin Oncol 17:3720-3728, 1999[Abstract/Free Full Text]

4. Spiegler BJ, Bouffet E, Greenberg ML, et al: Change in neurocognitive functioning after treatment with cranial radiation in childhood. J Clin Oncol 22:706-713, 2004[Abstract/Free Full Text]

5. Mulhern RK, White HA, Glass JO, et al: Attentional functioning and white matter integrity among survivors of malignant brain tumors of childhood. J Int Neuropsychol Soc 10:180-189, 2004[CrossRef][Medline]

6. Reddick WE, White HA, Glass JO, et al: Developmental model relating white matter volume to neurocognitive deficits in pediatric brain tumor survivors. Cancer 97:2512-2519, 2003[CrossRef][Medline]

7. Mulhern RK, Reddick WE, Palmer SL, et al: Neurocognitive deficits in medulloblastoma survivors and white matter loss. Ann Neurol 46:834-841, 1999[CrossRef][Medline]

8. Ball WS, Prenger EC, Ballard ET: Neurotoxicity of radio/chemotherapy in children: Pathologic and MR correlation. AJNR Am J Neuroradiol 13:761-776, 1992[Medline]

9. Curran WJ, Hecht-Leavitt C, Schut L, et al: Magnetic resonance imaging of cranial radiation lesions. Int J Radiat Oncol Biol Phys 13:1093-1098, 1987[Medline]

10. Constine LS, Konski A, Ekholm S, et al: Adverse effects of brain irradiation correlated with MR and CT imaging. Int J Radiat Oncol Biol Phys 15:319-330, 1988[CrossRef][Medline]

11. Tsuruda JS, Kortman KE, Bradley WG, et al: Radiation effects on cerebral white matter: MR evaluation. AJR Am J Roentgenol 149:165-171, 1987[Abstract/Free Full Text]

12. Mulhern RK, Palmer SL, Reddick WE, et al: Risks of young age for selected neurocognitive deficits in medulloblastoma are associated with white matter loss. J Clin Oncol 19:472-479, 2001[Abstract/Free Full Text]

13. Chu WCW, Chik KW, Chan YL, et al: White matter and cerebral metabolite changes in children undergoing treatment for acute lymphoblastic leukemia: Longitudinal study with MR imaging and H MR spectroscopy. Radiology 229:659-669, 2003[Abstract/Free Full Text]

14. Chan YL, Roebuck DJ, Yuen MP, et al: Long-term cerebral metabolite changes on proton magnetic resonance spectroscopy in patients cured of acute lymphoblastic leukemia with previous intrathecal methotrexate and cranial irradiation prophylaxis. Int J Radiat Oncol Biol Phys 50:759-763, 2001[CrossRef][Medline]

15. Khong PL, Kwong DLW, Chan GCF, et al: Diffusion-tensor imaging (DTI) for the detection and quantification of treatment-induced white matter injury in children with medulloblastoma: A pilot study. AJNR Am J Neuroradiol 24:734-740, 2003[Abstract/Free Full Text]

16. Leung LHT, Ooi GC, Kwong DL, et al: White-matter diffusion anisotropy after chemo-irradiation: A statistical parametric mapping study and histogram analysis. Neuroimage 21:261-268, 2004[CrossRef][Medline]

17. LeBihan D, Mangin JF, Poupon C, et al: Diffusion tensor imaging: Concepts and applications. J Magn Reson Imag 13:534-546, 2001[CrossRef][Medline]

18. Khong PL, Leung LH, Chan GCF, et al: White matter anisotropy in childhood medulloblastoma survivors: Association with neurotoxicity risk factors. Radiology 236:647-652

19. Nomura Y, Sakuma H, Tagami T, et al: Diffusional anisotropy of the human bran assessed with diffusion-weighted MR: Relation with normal brain development and aging. AJNR Am J Neuroradiol 15:231-238, 1994[Abstract]

20. Morriss MC, Zimmerman RA, Bilaniuk LT, et al: Changes in brain water diffusion during childhood. Neuroradiology 41:929-934, 1999[CrossRef][Medline]

21. Mukherjee P, Miller JH, Shimony JS, et al: Normal brain maturation during childhood: Developmental trends characterized with diffusion-tensor MR imaging. Radiology 221:349-358, 2001[Abstract/Free Full Text]

22. Philip JV, Mukherjee P, Neil JJ, et al: White matter maturation in older children demonstrated with diffusion tensor MRI. Proc Intl Soc Mag Reson Med 9:409, 2001

23. Nagy Z, Westerberg H, Klingberg T, et al: Maturation of white matter is associated with the development of cognitive functions during childhood. J Cogn Neurosci 16:1227-1233, 2004[CrossRef][Medline]

24. Peng SSF, Tseng WYI, Chien YH, et al: Diffusion tensor images in children with early-treated, chronic, malignant phenylketonuric: Correlation with intelligence assessment. AJNR Am J Neuroradiol 25:1569-1574, 2004[Abstract/Free Full Text]

25. Kantarci K, Jack CR, Xu YC, et al: Mild cognitive impairment and Alzheimer disease: Regional diffusivity of water. Radiology 219:101-107, 2001[Abstract/Free Full Text]

26. O'Sullivan M, Morris RG, Huckstep B, et al: Diffusion tensor MRI correlates with executive dysfunction in patients with ischaemic leukoaraiosis. J Neurol Neurosurg Psychiatry 75:441-447, 2004[Abstract/Free Full Text]

27. Rovaris M, Iannucci G, Falautano M, et al: Cognitive dysfunction in patients with mildly disabling relapsing-remitting multiple sclerosis: An exploratory study with diffusion tensor MR imaging. J Neurol Sci 195:103-109, 2002[CrossRef][Medline]

28. Steinlin M, Imfeld S, Zulauf P, et al: Neuropsychological long-term sequelae after posterior fossa tumour resection during childhood. Brain 126:1998-2008, 2003[Abstract/Free Full Text]

29. Riva D, Giorgi C: The cerebellum contributes to higher functions during development: Evidence from a series of children surgically treated for posterior fossa tumours. Brain 123:1051-1061, 2000[Abstract/Free Full Text]

30. Mabbott DJ, Spiegler BJ, Greenberg ML, et al: Serial evaluation of academic and behavioral outcome after treatment with cranial radiation in childhood. J Clin Oncol 23:2256-2263, 2005[Abstract/Free Full Text]

31. Moleski M: Neuropsychological, neuroanatomical, and neurophysiological consequences of CNS chemotherapy for acute lymphoblastic leukemia. Arch Clin Neuropsychol 15:603-630, 2000[CrossRef][Medline]

32. Ochs J, Mulhern R, Fairclough D, et al: Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: A prospective study. J Clin Oncol 9:145-151, 1991[Abstract/Free Full Text]

33. Giralt J, Ortega JJ, Olive T, et al: Long-term neuropsychologic sequelae of childhood leukemia: Comparison of two CNS prophylactic regimens. Int J Radiat Oncol Biol Phys 24:49-53, 1992[Medline]

34. Palmer SL, Goloubeva O, Reddick WE, et al: Patterns of intellectual development among survivors of pediatric medulloblastoma: A longitudinal analysis. J Clin Oncol 19:2302-2308, 2001[Abstract/Free Full Text]

35. Palmer SL, Gaijar A, Reddick WE, et al: Predicting intellectual outcome among children treated with 35-40 Gy craniospinal irradiation for medulloblastoma. Neuropsychology 17:548-555, 2003[CrossRef][Medline]

Submitted April 20, 2005; accepted December 5, 2005.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Am. J. Neuroradiol.Home page
W.E. Reddick, J.O. Glass, D.P. Johnson, F.H. Laningham, and C.-H. Pui
Voxel-Based Analysis of T2 Hyperintensities in White Matter during Treatment of Childhood Leukemia
AJNR Am. J. Neuroradiol., November 1, 2009; 30(10): 1947 - 1954.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
P.C. Sundgren
MR Spectroscopy in Radiation Injury
AJNR Am. J. Neuroradiol., September 1, 2009; 30(8): 1469 - 1476.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Wang, E. X. Wu, D. Qiu, L. H.T. Leung, H.-F. Lau, and P.-L. Khong
Longitudinal Diffusion Tensor Magnetic Resonance Imaging Study of Radiation-Induced White Matter Damage in a Rat Model
Cancer Res., February 1, 2009; 69(3): 1190 - 1198.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
J. M. Provenzale
Advances in Pediatric Neuroradiology: Highlights of the Recent Medical Literature
Am. J. Roentgenol., January 1, 2009; 192(1): 19 - 25.
[Abstract] [Full Text] [PDF]


Home page
J Child NeurolHome page
M. A. Askins and B. D. Moore III
Preventing Neurocognitive Late Effects in Childhood Cancer Survivors
J Child Neurol, October 1, 2008; 23(10): 1160 - 1171.
[Abstract] [PDF]


Home page
Neuro Oncol DukeHome page
W. Wick, R. Stupp, A.-C. Beule, J. Bromberg, A. Wick, U. Ernemann, M. Platten, C. Marosi, W. P. Mason, M. van den Bent, et al.
A novel tool to analyze MRI recurrence patterns in glioblastoma
Neuro-oncol, January 1, 2008; 10(6): 1019 - 1024.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. P. Waber, J. Turek, L. Catania, K. Stevenson, P. Robaey, I. Romero, H. Adams, C. Alyman, C. Jandet-Brunet, D. S. Neuberg, et al.
Neuropsychological Outcomes From a Randomized Trial of Triple Intrathecal Chemotherapy Compared With 18 Gy Cranial Radiation As CNS Treatment in Acute Lymphoblastic Leukemia: Findings From Dana-Farber Cancer Institute ALL Consortium Protocol 95-01
J. Clin. Oncol., November 1, 2007; 25(31): 4914 - 4921.
[Abstract] [Full Text] [PDF]


Home page
J Pediatr PsycholHome page
S. L. Palmer, W. E. Reddick, and A. Gajjar
Understanding the Cognitive Impact on Children Who are Treated for Medulloblastoma
J. Pediatr. Psychol., October 1, 2007; 32(9): 1040 - 1049.
[Abstract] [Full Text] [PDF]


Home page
J Pediatr PsycholHome page
M. D. Ris
Lessons in Pediatric Neuropsycho-Oncology: What We Have Learned Since Johnny Gunther
J. Pediatr. Psychol., October 1, 2007; 32(9): 1029 - 1037.
[Abstract] [Full Text] [PDF]


Home page
J Pediatr PsycholHome page
E. Mark Mahone, M. Cristine Prahme, K. Ruble, S. H. Mostofsky, and C. L. Schwartz
Motor and Perceptual Timing Deficits Among Survivors of Childhood Leukemia
J. Pediatr. Psychol., September 1, 2007; 32(8): 918 - 925.
[Abstract] [Full Text] [PDF]


Home page
Neuro Oncol DukeHome page
D. J. Mabbott, M. D. Noseworthy, E. Bouffet, C. Rockel, and S. Laughlin
Diffusion tensor imaging of white matter after cranial radiation in children for medulloblastoma: Correlation with IQ
Neuro-oncol, July 1, 2006; 8(3): 244 - 252.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Khong, P.-L.
Right arrow Articles by Chan, G. C.F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khong, P.-L.
Right arrow Articles by Chan, G. C.F.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online